# Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis

> **NCT04265092** · — · COMPLETED · sponsor: **Pôle Saint Hélier** · enrollment: 22 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Incobotulinum toxin A

## Key facts

- **NCT ID:** NCT04265092
- **Lead sponsor:** Pôle Saint Hélier
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-03
- **Final completion:** 2019-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04265092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04265092, "Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04265092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*